Riverside, CA Doe & Ingalls of California announced today that they have been selected by BioMarin Pharmaceutical Inc. to be a key supplier for high purity chemicals used in their commercial and clinical manufacturing processes. The decision follows the grand opening of Doe & Ingalls of CA’s cGMP compliant storage facility in Riverside, CA in April.
Due to increased risks caused by the globalization of the chemical supply chain, biotechnology companies are now requiring complete transparency from chemical manufacturers. With this comes a need for a supply chain partner with the expertise, understanding and capabilities to mitigate risks faced by the biotech industry. BioMarin has proactively partnered with Doe & Ingalls of California to ensure their risk and operational goals for raw materials are met. “With the increasingly stringent requirements being put on our supply chain we need to strengthen the integrity and security of our supply of raw materials. We are confident that the partnership with Doe & Ingalls of CA will allow us to meet these goals and yield improvements in our processes and bottom line.”
This new relationship will enable BioMarin to use Doe & Ingalls of CA’s warehouse as an extension of their own resulting in less need for hazardous storage at their facility. The brand new 43,000 square foot facility has 39,000 square feet of H3/H4 hazmat storage. They will utilize Doe & Ingalls of CA’s preshipment sampling program which includes plastic repalletization, customized product labeling and risk mitigation analysis among others.
“The globalization of the chemical supply chain and the vulnerabilities associated with it have many Biotech companies reaching out to us for secondary sourcing and risk assessments for their critical raw materials.” states John Hollenbach, Vice President & General Manager of Doe & Ingalls of CA. “To have a company of BioMarin’s reputation and stature choose us to assist in securing their supply chain demonstrates how well positioned we are to address many of the biotech industry’s supply chain concerns.”
Doe & Ingalls of North Carolina, parent company of D&I of CA, has been a leading chemical services provider to the biotechnology industry on the east coast since 1986. They have publicly showcased their expertise in the area of risk mitigation through a White Paper and numerous presentations at Biotech events.
About Doe & Ingalls of North Carolina
Doe & Ingalls of North Carolina helps biotechnology and microelectronic companies create reliable, secure supply chains for their critical raw materials. Its services include smart sourcing, chemical management programs and supply chain risk mitigation. The company’s locations include Tampa, Florida; Durham, North Carolina; Jessup, Maryland; and Riverside, California. For more information, visit www.doeingalls.com.
About BioMarin
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.
